FDA Approves Actemra to Treat Giant Cell Arteritis

Share this content:
FDA Approves Actemra to Treat Giant Cell Arteritis
FDA Approves Actemra to Treat Giant Cell Arteritis

MONDAY, May 22, 2017 (HealthDay News) -- The injected drug Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis.

Actemra was evaluated in clinical studies involving 251 patients with giant cell arteritis. Compared to patients receiving placebo with a standardized prednisone regimen, a higher number of patients receiving subcutaneous Actemra with a standardized prednisone regimen achieved sustained remission. Relative to placebo, the cumulative prednisone dose was lower in patients treated with Actemra.

The drug will carry a boxed label warning of the possibility of serious infections. For that reason, live vaccines should be avoided while taking the drug, the FDA said. And Actemra should be used with caution among patients at increased risk of gastrointestinal perforation or dangerous allergic-like hypersensitivity reactions, the agency added.

The Hoffmann-La Roche drug was first approved in 2010 for moderately-to-severely active rheumatoid arthritis. The company is based in Basel, Switzerland.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments

Online Nursing Education Can Up Patient Use of VTE Prophylaxis

Online Nursing Education Can Up Patient Use of ...

Online training aims to make sure those hospitalized get treatment to prevent venous thromboembolism

On-Pump CABG Leads to Higher Rates of Five-Year Survival

On-Pump CABG Leads to Higher Rates of Five-Year ...

Study compared coronary-artery bypass grafting surgery, with/without cardiopulmonary bypass

is free, fast, and customized just for you!

Already a member?

Sign In Now »